Jazz Pharmaceuticals Posts Record $1.2B Quarter, Raises Guidance
Jazz Pharmaceuticals reported record third-quarter 2026 revenues of $1.2 billion, a 10% year-over-year gain, and lifted its full-year revenue outlook.
Jazz Pharmaceuticals achieved record quarterly revenues of $1.2 billion in the third quarter of 2026, representing a 10% increase compared with the same period a year earlier, the company announced. The results prompted management to raise its full-year 2026 total revenue guidance, signaling confidence in sustained commercial momentum across its portfolio.
Xywav, the company's oxybate therapy, was a standout contributor, with revenues climbing 12% year-over-year. The drug added 425 net new patients during the quarter, indicating continued market penetration in its approved indications and suggesting the growth trajectory remains intact heading into the final quarter of the year.
Read more Tennessee Banker Kirk Goehring Wins ABA Emerging Leader Award →
The company also launched Ziihera in the first-line metastatic gastroesophageal adenocarcinoma setting for HER2-positive patients, marking an expansion into a new oncology segment. The launch represents a strategically significant move as Jazz seeks to diversify its revenue base beyond its established sleep and hematology franchises.
Further broadening its pipeline, Jazz closed the acquisition of Actio during the quarter. While financial terms were not detailed in the announcement, the deal adds undisclosed assets to the company's development portfolio, a pattern consistent with Jazz's longstanding strategy of supplementing organic growth with targeted acquisitions.
The combination of record top-line revenue, a raised guidance range, a new product launch, and a completed acquisition positions Jazz as one of the more active mid-sized specialty pharmaceutical companies heading into the end of 2026. Continue reading at Earnings.
